Saturday, October 3, 2026

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate

The Oasis Group rates wealth management and estate planning vendors while selling consulting services to the same market — a structural conflict regulators worldwide have scrutinized since 2008. The firm's 2026 Peaks for Estate Planning Platforms report is widely cited in fintech circles, raising questions about independence that remain publicly unanswered. No specific incident has been identified, but analysts rate the governance risk as major severity.

LM Salvado
LM Salvado

May 31, 2026

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Oasis Group rates wealth management and estate planning vendors while simultaneously selling consulting services to firms in that market — a conflict-of-interest model regulators worldwide confronted after the 2008 financial crisis.1

The firm publishes the 2026 Peaks for Estate Planning Platforms report, a benchmark widely cited in fintech and estate planning circles.1 It also operates across wealth management research, market analysis, and consulting — domains that overlap directly with the vendors it rates.

The structural problem is familiar internationally. When issuers pay for their own ratings, incentive structures degrade. That lesson drove post-crisis regulatory reform of traditional credit rating agencies in the U.S., EU, and across G20 markets. Independent research firms occupy a less regulated space — making voluntary governance the only real safeguard.

The core question: can a firm that earns consulting revenue or sponsorship fees from vendors it rates credibly guarantee independent assessments?1 Even with editorial controls in place, the financial relationship creates a structural conflict that undermines trust in outcomes.

Risk analysts rate the severity as major.1 Likelihood is rated low — no specific incident has been identified. But low likelihood does not neutralize a major-severity structural exposure. The conditions for conflict exist; that is the finding.

For institutional clients globally — using these rankings to make platform procurement or investment decisions — the practical question is whether independence is verified. Without published disclosure of client relationships, firewall policies, or third-party audits, it is not.

Governance best practice in research publishing requires affirmative separation: distinct editorial and commercial teams, disclosed conflicts, and independent oversight. Whether The Oasis Group has implemented such controls is not publicly documented.1

The wealth management sector depends on third-party research to evaluate fintech vendors. Ratings credibility is the product. Erosion of that credibility carries direct consequences for the firm's market position — and for clients acting on its outputs.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com